AGEN
Agenus Inc.
AGEN's fundamentals are mixed: revenue grew 25%, but free cash flow was negative. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
AGEN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.1x | $1.52 | -78% |
| Fair | 3.1x | $2.20 | -68% |
| Current | 9.7x | $6.87 | — |
| Expensive | 15x | $10.89 | +58% |
Historical ranges are pointers, not guarantees.
AGEN's PE is 9.7x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect AGEN's earnings and revenue to decline, though with profitability holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.71 | +$2.75 |
| Q2 2026 | $2.63 | +$9.69 |
| Q1 2026 | $1.64 | +$10.22 |
| Q4 2025 | -$0.41 | +$10.18 |
| Q3 2022 | -$14.52 | -$12.16 |
| Q2 2022 | $3.34 | +$25.32 |
| Q1 2022 | -$0.59 | +$19.63 |
| Q4 2021 | -$2.16 | +$18.84 |
AGEN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $31.5M | +4.1% |
| Q2 2026 | $34.5M | +34% |
| Q1 2026 | $33.7M | +40% |
| Q4 2025 | $34.2M | +27% |
| Q3 2025 | $30.2M | +20% |
| Q2 2025 | $25.7M | +9.3% |
| Q1 2025 | $24.1M | -14% |
| Q4 2024 | $26.8M | -68% |
AGEN's revenue has grown year over year for six quarters in a row: $31M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +51 points |
| Q2 2026 | 33% | +98 points |
| Q1 2026 | 45% | +100 points |
| Q4 2025 | 42% | +139 points |
| Q3 2025 | -15% | +110 points |
| Q2 2025 | -65% | +63 points |
| Q1 2025 | -55% | +62 points |
| Q4 2024 | -96% | -92 points |
AGEN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AGEN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.1M | -$5.4M |
| Q2 2026 | -$31.2M | -$11M |
| Q1 2026 | -$36M | -$10.3M |
| Q4 2025 | -$16.6M | +$12.1M |
| Q3 2025 | -$14.7M | +$38.6M |
| Q2 2025 | -$20.2M | +$18.4M |
| Q1 2025 | -$25.6M | +$12.6M |
| Q4 2024 | -$28.7M | +$11.9M |
AGEN has burned cash in almost every quarter: −$104M over the past year, against −$89M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +101% | +41.9M shares |
| 1 year | +196% | +55.2M shares |
| 3 years | +795% | +74M shares |
AGEN has 83M diluted shares, up 196% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $42,000 |
| Q3 2023 | $328,000 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | -0.3x | Net Cash |
| Q2 2022 | -3.6x | Net Cash |
| Q1 2022 | -6.1x | Net Cash |
| Q4 2021 | -8.6x | Net Cash |
| Q3 2021 | -3.7x | Net Cash |
AGEN has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 22.9 | Neutral |
AGEN's weekly RSI is 54 (neutral) and its Stochastic is 23 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AGEN PE vs Healthcare Sector
| Metric | AGEN | Sector median | Relative |
|---|---|---|---|
| PE | 9.7x | 26x | 62% below |
| PE % | 64 | 29 | 35 pts above |
AGEN is trading at 9.7x earnings, a 62% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.22 | 4.8% below |
| 20 week MA | $6.81 | 0.9% above |
| 50 week MA | $4.78 | 44% above |
| 100 week MA | $4.30 | 60% above |
| 200 week MA | $11.7 | 41% below |
AGEN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $82.8 | $67.7 | -18% |
| 2021 | $67.7 | $71.6 | +5.8% |
| 2022 | $71.6 | $49.1 | -32% |
| 2023 | $49.1 | $16.6 | -66% |
| 2024 | $16.6 | $2.75 | -83% |
| 2025 | $2.75 | $3.31 | +20% |
| 2026 YTD | $3.31 | $6.87 | +108% |
AGEN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.